文献速递细菌感染、耐药与抗菌药物

印度伤寒沙门菌与甲型副伤寒沙门菌抗菌药物敏感性分析:现状与未来管理策略

Evaluation of Antimicrobial Susceptibility Profile in Salmonella Typhi and Salmonella Paratyphi A: Presenting the Current Scenario in India and Strategy for Future Management.
PubMed 文献 · J Infect Dis · 2021-01-01

该多中心前瞻性监测研究在2017年11月至2020年1月的2年间收集2373株沙门菌,其中85.6%为伤寒沙门菌、14.4%为甲型副伤寒沙门菌。约2%的伤寒沙门菌为多重耐药,甲型副伤寒沙门菌100%对一线抗菌药物敏感;环丙沙星不敏感率约98%,伤寒沙门菌耐药比例(37%)高于甲型副伤寒沙门菌(20%)。作者认为应限制环丙沙星使用并合理使用阿奇霉素和头孢曲松。

要点

  • 2373株沙门菌中伤寒沙门菌占85.6%,甲型副伤寒沙门菌占14.4%。
  • 约2%的伤寒沙门菌为多重耐药,甲型副伤寒沙门菌100%对一线抗菌药物敏感。
  • 环丙沙星不敏感率约98%,头孢曲松是唯一保持100%敏感的药物。

核心结论

  • 该系统性监测研究证实印度多重耐药沙门菌分离株呈下降趋势。
  • 环丙沙星不敏感率较高,作者认为应限制其使用并坚持合理使用阿奇霉素和头孢曲松治疗肠热症。

研究设计与样本

  • 印度肠热症监测多中心研究,对2017年11月至2020年1月2年期间前瞻性收集的2373株伤寒沙门菌和甲型副伤寒沙门菌分离株进行抗菌药物敏感性试验。

主要发现

  • 2373株沙门菌中2032株(85.6%)为伤寒沙门菌,341株(14.4%)为甲型副伤寒沙门菌。
  • 约2%的伤寒沙门菌为多重耐药,而全部341株(100%)甲型副伤寒沙门菌对一线抗菌药物敏感。
  • 在约98%的环丙沙星不敏感分离株中,耐药(最低抑菌浓度[MIC] >0.5 µg/mL)在伤寒沙门菌(37%)中高于甲型副伤寒沙门菌(20%)。
  • 阿奇霉素敏感性在伤寒沙门菌为99.9%、在甲型副伤寒沙门菌为100%,平均MIC分别为4.98 μg/mL和7.39 μg/mL。
  • 头孢曲松是唯一保持100%敏感性的药物,β-内酰胺/β-内酰胺酶抑制剂对研究分离株显示出强效体外活性。

关键数值与推荐

  • 环丙沙星耐药定义为MIC >0.5 µg/mL。
  • 伤寒沙门菌中约2%为多重耐药。
  • 甲型副伤寒沙门菌341株(100%)对一线抗菌药物敏感。
  • 伤寒沙门菌阿奇霉素敏感性99.9%,平均MIC 4.98 μg/mL;甲型副伤寒沙门菌阿奇霉素敏感性100%,平均MIC 7.39 μg/mL。
  • 头孢曲松敏感性100%。

临床怎么用

  • 作者认为应限制环丙沙星的使用。
  • 作者认为应坚持合理使用阿奇霉素和头孢曲松治疗肠热症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systematic studies to estimate the disease burden of typhoid and paratyphoid in India are limited. Therefore, a multicenter study on the Surveillance of Enteric Fever in India was carried out to estimate the incidence, clinical presentation, and antimicrobial resistance (AMR) trend. The data presented here represent the national burden of AMR in Salmonella Typhi and Salmonella Paratyphi A. METHODS: Antimicrobial susceptibility testing was performed for S. Typhi and S. Paratyphi A (n = 2373) isolates collected prospectively during a 2-year period from November 2017 to January 2020. RESULTS: Of 2373 Salmonella isolates, 2032 (85.6%) were identified as S. Typhi and 341 (14.4%) were S. Paratyphi A. Approximately 2% of S. Typhi were multidrug-resistant (MDR), whereas all 341 (100%) of S. Paratyphi A isolates were sensitive to the first-line antimicrobials. Among 98% of ciprofloxacin nonsusceptible isolates, resistance (minimum inhibitory concentration [MIC] >0.5 µg/mL) was higher in S. Typhi (37%) compared with S. Paratyphi A (20%). Azithromycin susceptibility was 99.9% and 100% with a mean MIC of 4.98 μg/mL for S. Typhi and 7.39 μg/mL for S. Paratyphi A respectively. Ceftriaxone was the only agent that retained 100% susceptibility. Moreover, beta-lactam/beta-lactamase inhibitors showed potent in vitro activity against the study isolates. CONCLUSIONS: Data obtained from this systematic surveillance study confirms the declining trend of MDR Salmonella isolates from India. The higher prevalence of ciprofloxacin nonsusceptibility enforces to limit its use and adhere to the judicious usage of azithromycin and ceftriaxone for enteric fever management.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Veeraraghavan B, Pragasam AK, Ray P, et al. Evaluation of Antimicrobial Susceptibility Profile in Salmonella Typhi and Salmonella Paratyphi A: Presenting the Current Scenario in India and Strategy for Future Management. J Infect Dis. 2021. PMID: 35238369. doi:10.1093/infdis/jiab144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。